Evidence map›Paper›PMID 35221731›Full record

ReviewClinical pharmacology : advances and applications2022

Antileishmanial Activity of Tamoxifen by Targeting Sphingolipid Metabolism: A Review.

Kaleab Alemayehu Zewdie, Haftom Gebregergs Hailu, Muluken Altaye Ayza, Bekalu Amare Tesfaye

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Clinical pharmacology : advances and applications, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 2 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Kaleab Alemayehu ZewdieDepartment of Pharmacology and Toxicology, School of Pharmacy, Mekelle University, Mekelle, Ethiopia.ORCID 0000-0002-7089-421X
Haftom Gebregergs HailuDepartment of Pharmacology and Toxicology, School of Pharmacy, Mekelle University, Mekelle, Ethiopia.ORCID 0000-0002-9135-9638
Muluken Altaye AyzaDepartment of Pharmacology and Toxicology, School of Pharmacy, Mekelle University, Mekelle, Ethiopia.ORCID 0000-0001-6196-0361
Bekalu Amare TesfayeDepartment of Pharmacology and Toxicology, School of Pharmacy, Mekelle University, Mekelle, Ethiopia.ORCID 0000-0001-9743-0346
Mekelle University · ET

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Leishmaniasis is a widespread group of neglected parasitic diseases caused by protozoa of the genus

Indexed as

estrogen receptor modulatorleishmaniasissphingolipid metabolismtamoxifen

Identifiers

PMID35221731
PMCPMC8880078
OpenAlexW4213118632

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.